Watch Our Story in Action

Latest Updates

AbstimX™ Enters Clinical Testing

Network Immunology has initiated a clinical trial evaluating AbstimX™, its first-in-class immune-modulating therapy designed to restore immune balance without suppression.

Because dogs naturally develop allergic and inflammatory conditions that closely resemble human disease, this study provides important translational data on safety, immune response, and early efficacy. The results will help de-risk and accelerate AbstimX™’s advancement into human clinical development.

Network Immunology has formed a Clinical Advisory Board composed of experienced physicians and translational experts in inflammatory and autoimmune disease. This board will provide strategic guidance on clinical trial design, regulatory pathways, and target indications as AbstimX™ advances toward human studies.

The addition of a Clinical Advisory Board strengthens our development strategy, enhances regulatory readiness, and ensures that our programs are aligned with real-world clinical needs—further accelerating our path toward human therapeutic applications.